Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | METAP1 | P53582 | 5/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PPIB | P23284 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878160 | 1.00 | ACHE (0.55) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL14274030 | 0.71 | ACHE (0.61) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL13497540 | 0.71 | ACHE (0.61) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL13497521 | 0.71 | ACHE (0.61) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL14308407 | 0.71 | ACHE (0.61) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL29894949 | 0.71 | ACHE (1.00) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL3860892 | 0.71 | ACHE (1.00) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL14395400 | 0.70 | ACHE (0.60) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL1180262 | 0.70 | ACHE (0.69) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL16311356 | 0.70 | ACHE (0.69) | ACHEMETAP1CYP19A1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | ACHE 31/4885METAP1 909/4885CYP19A1 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.